ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2157

Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases

Bunyamin Kisacik1, Omer Pamuk2, Ahmet Mesut Onat3, B. Erer4, Gulen Hatemi5, Yesim Ozguler6, Yavuz Pehlivan7, Levent Kilic8, Ihsan Ertenli8, Meryem Can9, Haner Direskeneli9, Gökhan Keser10, Fahrettin Oksel10, Ediz Dalkilic11, Sedat Yilmaz12, Salih Pay13, Ayse Balkarli14, Veli Cobankara15, Gozde Yildirim Cetin16, Mehmet Sayarlioglu17, Ayse Cefle18, Ayten Yazici18, Ali Berkant Avci19, Ender Terzioglu20, Suleyman Ozbek21, Servet Akar22 and Ahmet Gül23, 1Rheumatology, Gaziantep University, School of Medicine, Gaziantep, Turkey, 2Trakya Üniversitesi, edirne, Turkey, 3Rheumatology, Gaziantep University School of Medicine, Gaziantep, Turkey, 4Istanbul Faculty of Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 5Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 6University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 7Rheumatology, Uludag University, School of Medicine, Bursa, Turkey, 8Hacettepe Üniversity, Ankara, Turkey, 9Marmara Üniversitesi, Ýstanbul, Turkey, 10Ege Üniversitesi, Ýzmir, Turkey, 11Uludað Üniversitesi, Bursa, Turkey, 12GATA, ANKARA, Turkey, 13GATA, Ankara, Turkey, 14Pamukkale Üniversitesi, Denizli, Turkey, 15Denizli Üniversitesi, Denizli, Turkey, 16Deparment of Rheumatology, Sutcu Imam University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Kahramanmaras, Turkey, 17Rheumatology, Ondokuz Mayis University School of Medicine, Samsun, Turkey, 18Department of Rheumatology, Kocaeli University, Kocaeli, Turkey, 19Antalya University, School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey, 20School of Medicine, Akdeniz University, Antalya, Turkey, 21Cukurova Üniversitesi, Adana, Turkey, 22Katip Çelebi Üniversitesi, Ýzmir, Turkey, 23Department of Internal Medicine, Rheumatology Division, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Biologic agents and tuberculosis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Infections, Infection-related Biomarkers and Impact of Biologic Therapies

Session Type: Abstract Submissions (ACR)

Background/Purpose

Tumor necrosis factor alpha inhibitors (anti-TNF) are a breakthrough for the treatment of inflammatory rheumatic diseases and tuberculosis (TB) is the prevailing and vitally important infectious complication. This retrospective data analyzes the risk of tuberculosis reactivation and demographic features of patients treated with anti-TNF drugs in Turkey, where TB is still a widespread endemic disease.

Methods

The study is held by Turkish Multi-centered Investigators Platform in Rheumatology (TULIP).10.434 patients treated with anti-TNF drugs, 73 (0.69%) patients were diagnosed with TB (M/F: 39/34), 7.695 patients with accurate and complete data of laboratory and clinical history were enrolled as control group.

Results

Among 73 patients diagnosed with TB, 38 patients were diagnosed with ankylosing spondylitis, 25 with rheumatoid arthritis, 4 with psoriatic arthritis, 5 with Behcet’s syndrome, and a patient with vasculitis. TB frequency in patients using infliximab (1.27%) was significantly higher than  patients using etanercept (0.3%) and adalimumab (0.57%) (p <0.001 and 0.008, respectively). Six patients out of 73 TB cases (8.2%) died under follow-up. Thirty-four cases (46.6%) out of 73 TB patients had pulmonary tuberculosis. In the logistic regression model, type of anti-TNF (infliximab) (OR: 3.4, 95%CI: 1.88-6.1, p=0.001) and insufficient prophylaxis (<9 months) (OR: 3.15, 95%CI: 1.43- 6.9, p=0.004) were independent predictors of TB development among anti-TNF treated patients.

Conclusion

Our results suggest that TB is an important complication of anti-TNF therapies in Turkey, where the disease is still endemic. TB chemoprophylaxis less than nine months and the use infliximab therapy were independent risk factors for TB development.


Disclosure:

B. Kisacik,
None;

O. Pamuk,
None;

A. M. Onat,
None;

B. Erer,
None;

G. Hatemi,
None;

Y. Ozguler,
None;

Y. Pehlivan,
None;

L. Kilic,
None;

I. Ertenli,
None;

M. Can,
None;

H. Direskeneli,
None;

G. Keser,
None;

F. Oksel,
None;

E. Dalkilic,
None;

S. Yilmaz,
None;

S. Pay,
None;

A. Balkarli,
None;

V. Cobankara,
None;

G. Yildirim Cetin,
None;

M. Sayarlioglu,
None;

A. Cefle,
None;

A. Yazici,
None;

A. B. Avci,
None;

E. Terzioglu,
None;

S. Ozbek,
None;

S. Akar,
None;

A. Gül,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tuberculosis-reactivation-risk-in-patients-treated-with-tumor-necrosis-factor-alpha-inhibitors-a-turkish-experience-with-higher-mortality-and-different-background-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.